Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept plus calcineurin inhibitors for refractory systemic lupus erythematosus with thrombocytopenia
ChiCTR2300074080Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jul 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of telitacicept in systemic lupus erythematosus (SLE), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Platelet count level. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
telitacicept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ChiCTR2300074080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074080.